{
    "nctId": "NCT06382142",
    "briefTitle": "A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer",
    "officialTitle": "A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure",
    "overallStatus": "RECRUITING",
    "conditions": "Triple-Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 406,
    "primaryOutcomeMeasure": "Progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Voluntarily sign the informed consent and follow the requirements of the protocol;\n2. No gender limit;\n3. Age \u226518 years old and \u226475 years old;\n4. Expected survival time \u22653 months;\n5. Patients with unresectable, locally advanced or metastatic triple-negative breast cancer;\n6. Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;\n7. The subjects had received 1-2 lines of chemotherapy regimens in the locally advanced or metastatic stage, and had been treated with taxanes previously;\n8. Acceptability of chemotherapy with eribulin, capecitabine, gemcitabine, or vinorelbine, as assessed by the investigator;\n9. Patients with baseline brain metastases should have received treatment for all brain metastases and be stable;\n10. Must have at least one measurable lesion that meets the RECIST v1.1 definition;\n11. ECOG score 0 or 1;\n12. Toxicity of previous antineoplastic therapy has returned to \u2264 grade 1 defined by NCI-CTCAE v5.0;\n13. No severe cardiac dysfunction, left ventricular ejection fraction \u226550%;\n14. No blood transfusion, no use of cell growth factors and/or platelet raising drugs within 14 days before the first use of the study drug, and the organ function level must meet the requirements;\n15. Coagulation function: international normalized ratio \u22641.5, and activated partial thromboplastin time \u22641.5\u00d7ULN;\n16. Urine protein \u22642+ or \\< 1000mg/24h;\n17. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Prior receipt of an ADC with a TOPI inhibitor as a toxin;\n2. Prior receipt of an ADC or antibody drug targeting EGFR and/or HER3;\n3. Chemotherapy, biological therapy, immunotherapy, etc. within 4 weeks or 5 half-lives before the first dose, small molecule targeted therapy within 5 days, palliative radiotherapy and anti-tumor therapy within 2 weeks;\n4. Anthracycline equivalent cumulative dose of adriamycin \\> 360 mg/m2;\n5. History of severe cardiovascular or cerebrovascular disease;\n6. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening;\n7. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;\n8. Active malignancy diagnosed within 5 years before randomization;\n9. Hypertension poorly controlled by two antihypertensive drugs;\n10. Patients with poor blood glucose control before the first dose;\n11. A history of interstitial lung disease requiring steroid therapy, or current radiation pneumonitis, or a suspicion of such disease;\n12. Complicated with pulmonary diseases leading to clinically severe respiratory impairment;\n13. Patients with carcinomatous meningitis (meningeal metastasis) or brain stem metastasis or spinal cord compression;\n14. Have a history of allergy to recombinant humanized antibodies or any of the ingredients of BL-B01D1;\n15. A history of autologous or allogeneic stem cell transplantation;\n16. Human immunodeficiency virus antibody positive, active hepatitis B virus infection, or hepatitis C virus infection;\n17. Severe infection within 4 weeks before randomization; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;\n18. Patients with massive or symptomatic effusions or poorly controlled effusions;\n19. Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;\n20. Were receiving long-term systemic corticosteroids or equivalent active anti-inflammatory drugs or any form of immunosuppressive therapy before randomization;\n21. Received other unmarketed investigational drug or treatment within 4 weeks before the first dose;\n22. Patients with superior vena cava syndrome should not be rehydrated;\n23. A history of severe neurological or mental illness;\n24. Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;\n25. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n26. History of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection or presence of Crohn's disease, ulcerative colitis, or chronic diarrhea;\n27. Patients scheduled for vaccination or receiving live vaccine within 28 days before the first dose;\n28. Other circumstances that were assessed by the investigator as inappropriate for participation in the trial.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}